CORT vs LLY
As of Sep 20, 2026, Corcept Therapeutics (CORT) scores 4.9/10 and ELI LILLY (LLY) 7.2/10 on AlphaStocks' five-model composite, so LLY scores higher. LLY trades 76% above its model fair value.
CORT
CORCEPT THERAPEUTICS INC
4.9
Weak
$110.35
LLY
ELI LILLY & Co
7.2
Consider Buy
$1,152.46
CORT vs LLY: Which is the Better Investment?
CORCEPT THERAPEUTICS INC (CORT) scores 4.9/10 while ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' composite model. ELI LILLY & Co has the higher composite rating of Consider Buy. On a P/E basis, ELI LILLY & Co trades at 50.2x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | CORT | LLY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 4.9/10 | 7.2/10▲ |
| Rating | Weak | Consider Buy▲ |
| Price | $110.35 | $1,152.46 |
| P/E Ratio | 132.9 | 50.2▲ |
| ROE | 10.5% | 82.0%▲ |
| Market Cap | $12B | $1.0T |
| Fair Value | — | $656.48 |
| Dividend Yield | — | 0.5% |
| Sector Rank | #116 of 168 | #11 of 168▲ |
| Model Verdicts | ||
| Piotroski | Neutral | Strong▲ |
| Buffett | Caution | Strong▲ |
| Graham | Caution | Caution |
| Lynch | Neutral | Neutral |
| Greenblatt | Limited Data | Caution▲ |
Related comparisons
CORT vs LLY: Which Stock Scores Higher?
CORCEPT THERAPEUTICS INC (CORT) and ELI LILLY & Co (LLY) are both in the Health Care sector. LLY currently leads with a composite score of 7.2/10 (Consider Buy) compared to CORT's 4.9/10 (Weak).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer